[1]	Cynthia M, Sumaiya A, Lina B, et al. Pregnancy after cancer:FIGO Best practice advice[J]. Int J Gynaecol Obstet, 2025, 169(3):1119-1126. DOI:10.1002/ijgo.70139. Cited in this article [1]

[2]	You L, Lv Z, Li C, et al. Worldwide cancer statistics of adolescents and young adults in 2019:a systematic analysis of the Global Burden of Disease Study 2019[J]. ESMO Open, 2021, 6(5):100255. DOI:10.1016/j.esmoop.2021.100255. Cited in this article [1]

[3]	Shnorhavorian M, Harlan LC, Smith AW, et al. Fertility preservation knowledge,counseling,and actions among adolescent and young adult patients with cancer:A population-based study[J]. Cancer, 2015, 121(19):3499-3506. DOI:10.1002/cncr.29328. Cited in this article [1]

[4]	中国抗癌协会宫颈癌专业委员会. 子宫颈癌筛查规范(2025年版)[J]. 中国实用妇科与产科杂志, 2025, 41(3):332-337. DOI:10.19538/j.fk2025030115. Cited in this article [1]

[5]	Li S, Hu T, Lv W, et al. Changes in prevalence and clinical characteristics of cervical cancer in the People's Republic of China:a study of 10,012 cases from a nationwide working group[J]. Oncologist, 2013, 18(10):1101-1107. DOI:10.1634/theoncologist.2013-0123. Cited in this article [1]

[6]	Contreras NA, Sabadell J, Verdaguer P, et al. Fertility-sparing approaches in atypical endometrial hyperplasia and endometrial cancer patients:current evidence and future directions[J]. Int J Mol Sci, 2022, 23(5):2531. DOI:10.3390/ijms23052531. Cited in this article [2]

[7]	Navarria I, Usel M, Rapiti E, et al. Young patients with endometrial cancer:how many could be eligible for fertility-sparing treatment[J]. Gynecol Oncol, 2009, 114(3):448-451. DOI:10.1016/j.ygyno.2009.05.038. Cited in this article [1]

[8]

Peng H, Jiang J, Li L, et al. Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia receiving fertility-preserving treatment[J]. Gynecol Oncol, 2024, 186:154-160. DOI:10.1016/j.ygyno.2024.04.013. Cited in this article [1]

[9]	Rodolakis A, Scambia G, Planchamp F, et al. ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma[J]. Hum Reprod Open, 2023, 2023(1): hoac057. DOI:10.1093/hropen/hoac057. Cited in this article [1]

[10]	Crafton SM, Cohn DE, Llamocca EN, et al. Fertility-sparing surgery and survival among reproductive-age women with epithelial ovarian cancer in 2 cancer registries[J]. Cancer, 2020, 126(6):1217-1224. DOI:10.1002/cncr.32620. Cited in this article [1]

[11]

Hu L, Yang H, Luo H, et al. Age-specific reference ranges and variation of anti-mülerian hormone in healthy Chinese women of reproductive and perimenopausal age:a nationwide population-based prospective multicenter cross-sectional study[J]. Gynecol Endocrinol, 2025, 41(1):2431230. DOI:10.1080/09513590.2024.2431230. Cited in this article [1]

[12]	Dewailly D, Andersen CY, Balen A, et al. The physiology and clinical utility of anti-Mullerian hormone in women[J]. Hum Reprod Update, 2014, 20(3):370-385. DOI:10.1093/humupd/dmt062. Cited in this article [2]

[13]	Lie Fong S, Visser JA, Welt CK, et al. Serum anti-müllerian hormone levels in healthy females:a nomogram ranging from infancy to adulthood[J]. J Clin Endocrinol Metab, 2012, 97(12):4650-4655. DOI:10.1210/jc.2012-1440. Cited in this article [1]

[14]	Practice Committee of the American Society for Reproductive Medicine. Fertility evaluation of infertile women:a committee opinion[J]. Fertil Steril, 2021, 116(5):1255-1265. DOI:10.1016/j.fertnstert.2021.08.038. Cited in this article [2]

[15]	Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve:a committee opinion[J]. Fertil Steril, 2020, 114(6):1151-1157. DOI:10.1016/j.fertnstert.2020.09.134. Cited in this article [1]

[16]	Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy[J]. Oncologist, 2006, 11(5):422-434. DOI:10.1634/theoncologist.11-5-422. Cited in this article [1]

[17]	Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte[J]. Hum Reprod, 2003, 18(1):117-121. DOI:10.1093/humrep/deg016. Cited in this article [1]

[18]

Meacham LR, Burns K, Orwig KE, et al. Standardizing risk assessment for treatment-related gonadal insufficiency and infertility in childhood adolescent and young adult cancer:the pediatric initiative network risk stratification system[J]. J Adolesc Young Adult Oncol, 2020, 9(6):662-666. DOI:10.1089/jayao.2020.0012. Cited in this article [1]

[19]	Hussein RS, Khan Z, Zhao Y. Fertility preservation in women:indications and options for therapy[J]. Mayo Clin Proc, 2020, 95(4):770-783. DOI:10.1016/j.mayocp.2019.10.009. Cited in this article [1]

[20]	Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy:a committee opinion[J]. Fertil Steril, 2019, 112(6):1022-1033. DOI:10.1016/j.fertnstert.2019.09.013. Cited in this article [1]

[21]	Hansen KR, Knowlton NS, Thyer AC, et al. A new model of reproductive aging:the decline in ovarian non-growing follicle number from birth to menopause[J]. Hum Reprod, 2008, 23(3):699-708. DOI:10.1093/humrep/dem408. Cited in this article [1]

[22]	ACOG. Female age-related fertility decline. Committee Opinion No. 589[J]. Fertil Steril, 2014, 101(3):633-634. DOI:10.1016/j.fertnstert.2013.12.032. Cited in this article [2]

[23]	Mahajan NK. Optimizing advice and approaches for elective fertility preservation[J]. Best Pract Res Clin Obstet Gynaecol, 2025, 99:102591. DOI:10.1016/j.bpobgyn.2025.102591. Cited in this article [1]

[24]	Emrich NLA, Einenkel R, Färber CM, et al. Ovarian tissue cryopreservation for fertility preservation:a two-decade single-center experience with 451 children and adolescents[J]. Reprod Biol Endocrinol, 2025, 23(1):51. DOI:10.1186/s12958-025-01388-x. Cited in this article [1]

[25]	Su HI, Lacchetti C, Letourneau J, et al. Fertility preservation in people with cancer:asco guideline update[J]. J Clin Oncol, 2025, 43(12):1488-1515. DOI:10.1200/JCO-24-02782. Cited in this article [2]

[26]	Grubliauskaite M, van der Perk MEM, Bos AME, et al. Minimal infiltrative disease identification in cryopreserved ovarian tissue of girls with cancer for future use:a systematic review[J]. Cancers (Basel), 2023, 15(17):4199. DOI:10.3390/cancers15174199. Cited in this article [1]

[27]

Lambertini M, Moore HCF, Leonard RCF, et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer:a systematic review and meta-analysis of individual patient-level data[J]. J Clin Oncol, 2018, 36(19):1981-1990. DOI:10.1200/JCO.2018.78.0858. Cited in this article [1]

[28]	Roberts JE, Benoit J, Foong S, et al. Fertility preservation in patients undergoing gonadotoxic treatments:a Canadian Fertility and Andrology Society clinical practice guideline[J]. Reprod Biomed Online, 2024, 48(5):103767. DOI:10.1016/j.rbmo.2023.103767. Cited in this article [1]

[29]	Bai F, Lu Y, Wu K, et al. Protecting effects of gonadotropin-releasing hormone agonist on chemotherapy-induced ovarian damage in premenopausal breast cancer patients:a systematic review and meta-analysis[J]. Breast Care (Basel), 2017, 12(1):48-52. DOI:10.1159/000454983. Cited in this article [1]

[30]

Munhoz RR, Pereira AA, Sasse AD, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer:a systematic review and meta-analysis[J]. JAMA Oncol, 2016, 2(1):65-73. DOI:10.1001/jamaoncol.2015.3251. Cited in this article [1]

[31]	Dolmans MM, Taylor HS, Rodriguez-Wallberg KA, et al. Utility of gonadotropin-releasing hormone agonists for fertility preservation in women receiving chemotherapy:pros and cons[J]. Fertil Steril, 2020, 114(4):725-738. DOI:10.1016/j.fertnstert.2020.08.011. Cited in this article [1]

[32]

Hwang JH, Yoo HJ, Park SH, et al. Association between the location of transposed ovary and ovarian function in patients with uterine cervical cancer treated with (postoperative or primary) pelvic radiotherapy[J]. Fertil Steril, 2012, 97(6):1387-1393.e932. DOI:10.1016/j.fertnstert.2012.02.052. Cited in this article [1]

[33]	Buonomo B, Multinu F, Casarin J, et al. Ovarian transposition in patients with cervical cancer prior to pelvic radiotherapy:a systematic review[J]. Int J Gynecol Cancer, 2021, 31(3):360-370. DOI:10.1136/ijgc-2020-001774. Cited in this article [1]

[34]	Perri T, Ben-Baruch G, Davidson T, et al. Use of titanium spiral tacks for long-term oophoropexy before pelvic irradiation[J]. Int J Gynecol Cancer, 2014, 24(6):1133-1136. DOI:10.1097/IGC.0000000000000146. Cited in this article [1]

[35]	Morice P, Juncker L, Rey A, et al. Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination[J]. Fertil Steril, 2000, 74(4):743-748. DOI:10.1016/s0015-0282(00)01500-4. Cited in this article [1]

[36]	Schuurman T, Zilver S, Samuels S, et al. Fertility-sparing surgery in gynecologic cancer:a systematic review[J]. Cancers (Basel), 2021, 13(5):1008. DOI:10.3390/cancers13051008. Cited in this article [1]

[37]

Morice P, Scambia G, Abu-Rustum NR, et al. Fertility-sparing treatment and follow-up in patients with cervical cancer,ovarian cancer,and borderline ovarian tumours:guidelines from ESGO,ESHRE,and ESGE[J]. Lancet Oncol, 2024, 25(11):e602-e610. DOI:10.1016/S1470-2045(24)00262-6. Cited in this article [3]

[38]	Dargent D, Franzosi F, Ansquer Y, et al. La trachélectomie élargie,risque de rechute plaidoyer pour un protocole de décision partagée[J]. Bull Cancer, 2002, 89(12):1027-1030. Cited in this article [1]

[39]	Šimják P, Cibula D, Pařízek A, et al. Management of pregnancy after fertility-sparing surgery for cervical cancer[J]. Acta Obstet Gynecol Scand, 2020, 99(7):830-838. DOI:10.1111/aogs.13917. Cited in this article [1]

[40]	程文俊. 卵巢恶性肿瘤生育力保存问题[J]. 中国实用妇科与产科杂志, 2024, 40(11):1082-1086.DOI:10.19538/j.fk2024110107. Cited in this article [1]

[41]	Kyrgiou M, Athanasiou A, Kalliala IEJ, et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease[J]. Cochrane Database Syst Rev, 2017, 11(11):CD012847. DOI:10.1002/14651858.CD012847. Cited in this article [1]

[42]	Nitecki R, Floyd J, Lamiman K, et al. Outcomes of the first pregnancy after fertility-sparing surgery for early-stage cervical cancer[J]. Obstet Gynecol, 2021, 138(4):565-573. DOI:10.1097/AOG.0000000000004532. Cited in this article [1]

[43]	Plante M. Vaginal radical trachelectomy:an update[J]. Gynecol Oncol, 2008, 111(2 Suppl):S105-S110. DOI:10.1016/j.ygyno.2008.07.020. Cited in this article [1]

[44]	Peccatori FA, Azim HA, Orecchia R, et al. Cancer, pregnancy and fertility:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J]. Ann Oncol, 2013, 24(6):vi160-vi170. DOI:10.1093/annonc/mdt199. Cited in this article [1]

[45]	La Marca A, Pati M, Orvieto R, et al. Serum anti-müllerian hormone levels in women with secondary amenorrhea[J]. Fertil Steril, 2006, 85(5):1547-1549. DOI:10.1016/j.fertnstert.2005.10.057. Cited in this article [1]

[46]	盛超, 王志坚. 优化妊娠间隔改善妊娠结局[J]. 中国实用妇科与产科杂志, 2023, 39(6):581-584.DOI:10.19538/j.fk2023060102. Cited in this article [1]